Use of atypical antipsychotics for post-hospitalization delirium and associated clinical outcomes in older adults

Abstract Atypical antipsychotic medications (APMs) are commonly prescribed to manage delirium symptoms among hospitalized older adults, but their comparative safety beyond hospital discharge remains unknown. This retrospective cohort study utilized Medicare 2013-2018 and Optum Clinformatics® 2013-2024 to examine the risks of clinical outcomes between quetiapine, risperidone, and olanzapine use among older adults following hospitalization. We included patients aged≥65 years without psychiatric disorders who newly filled quetiapine, risperidone, or olanzapine within 30 days of hospital discharge. The index date was the first dispensing date of the APM. Propensity score overlap weighting was employed to balance baseline covariates. Outcomes included all-cause mortality, all-cause rehospitalization, and specific rehospitalization causes. The on-treatment effects were measured using Poisson regression model. Analyses were conducted in the two databases separately and the effect estimates were pooled by fixed-effect meta-analysis. A total of 32,209, 9,732, and 6,363 quetiapine, risperidone, and olanzapine users were identified. The mortality rate (per 1000 person-years) was 478.1 for quetiapine (reference), 544.3 for risperidone (rate ratio [95% CI]: 1.11 [0.96-1.29]), and 726.2 for olanzapine (1.49 [1.30-1.71]). The rehospitalization rate was 1,408.6 for quetiapine (reference), 1,540.6 for risperidone (1.07 [0.97-1.17]), and 1,703.2 for olanzapine (1.16 [1.06-1.29]). Olanzapine also showed a significantly higher risk of death (1.34 [1.17-1.53]) compared to risperidone. Among rehospitalization reasons, olanzapine was associated with an increased risk of delirium compared to quetiapine (1.34 [1.12-1.60]) and risperidone (1.20 [1.01-1.42]). Our findings suggest that olanzapine increased the risks of adverse outcomes compared to risperidone and quetiapine among older adults prescribed with APMs after hospital discharge.

Authors

Institutions

Publication Details

Journal
Innovation in Aging
Published
2025-12-01
DOI
https://doi.org/10.1093/geroni/igaf122.1652
Primary Topic
Intensive Care Unit Cognitive Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of atypical antipsychotics for post-hospitalization delirium and associated clinical outcomes in older adults

James M. Wilkins, Chun‐Ting Yang, J. C. Lin, Kevin T. Pritchard et al.
Innovation in Aging
Intensive Care Unit Cognitive Disorders
article

Use of atypical antipsychotics for post-hospitalization delirium and associated clinical outcomes in older adults

James M. Wilkins, Chun‐Ting Yang, J. C. Lin, Kevin T. Pritchard, Xin Liu, Dae Hyun Kim
article en

Abstract

Abstract Atypical antipsychotic medications (APMs) are commonly prescribed to manage delirium symptoms among hospitalized older adults, but their comparative safety beyond hospital discharge remains unknown. This retrospective cohort study utilized Medicare 2013-2018 and Optum Clinformatics® 2013-2024 to examine the risks of clinical outcomes between quetiapine, risperidone, and olanzapine use among older adults following hospitalization. We included patients aged≥65 years without psychiatric disorders who newly filled quetiapine, risperidone, or olanzapine within 30 days of hospital discharge. The index date was the first dispensing date of the APM. Propensity score overlap weighting was employed to balance baseline covariates. Outcomes included all-cause mortality, all-cause rehospitalization, and specific rehospitalization causes. The on-treatment effects were measured using Poisson regression model. Analyses were conducted in the two databases separately and the effect estimates were pooled by fixed-effect meta-analysis. A total of 32,209, 9,732, and 6,363 quetiapine, risperidone, and olanzapine users were identified. The mortality rate (per 1000 person-years) was 478.1 for quetiapine (reference), 544.3 for risperidone (rate ratio [95% CI]: 1.11 [0.96-1.29]), and 726.2 for olanzapine (1.49 [1.30-1.71]). The rehospitalization rate was 1,408.6 for quetiapine (reference), 1,540.6 for risperidone (1.07 [0.97-1.17]), and 1,703.2 for olanzapine (1.16 [1.06-1.29]). Olanzapine also showed a significantly higher risk of death (1.34 [1.17-1.53]) compared to risperidone. Among rehospitalization reasons, olanzapine was associated with an increased risk of delirium compared to quetiapine (1.34 [1.12-1.60]) and risperidone (1.20 [1.01-1.42]). Our findings suggest that olanzapine increased the risks of adverse outcomes compared to risperidone and quetiapine among older adults prescribed with APMs after hospital discharge.

Innovation in AgingVol. 9(Supplement_2)
Brigham and Women's Hospital (US), McLean Hospital (US), Hebrew SeniorLife (US)
Good health and well-being
Openalex Percentile: Top 30%
Intensive Care Unit Cognitive Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.